Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus BETOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus BETOPTIC.
BETAGAN vs BETOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker